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Cytokines are important in adult hematopoiesis, yet
their function in embryonic hematopoiesis has been
largely unexplored. During development, hematopoi-
etic stemcells (HSCs) are found in theaorta-gonad-me-
sonephros (AGM) region, yolk sac (YS), and placenta
and require theRunx1 transcription factor for their nor-
mal generation. Since IL-3 is a Runx1 target and this
cytokine acts on adult hematopoietic cells, we exam-
ined whether IL-3 affects HSCs in the mouse embryo.
UsingRunx1 haploinsufficient mice, we show that IL-3
amplifiesHSCs fromE11AGM,YS, andplacenta.More-
over, weshow that IL-3mutant embryos are deficient in
HSCs and that IL-3 reveals the presence of HSCs in the
AGM and YS prior to the stage at which HSCs are nor-
mally detected. Thus, our studies support an unex-
pected role for IL-3 during development and strongly
suggest that IL-3 functions as a proliferation and/or
survival factor for the earliest HSCs in the embryo.
Introduction
Hematopoietic stem cells (HSCs) are rare self-renewing,
multipotential cells localized in the bone marrow (BM) of
the adult. HSCs extensively proliferate and differentiate
into myeloid and lymphoid lineages to constantly replen-
ish mature blood cells. In the adult, many growth factors
regulate hematopoietic processes during homeostasis
and trauma. Among these is IL-3, one of the earliest
identified cytokines (Ihle et al., 1981). Extensive in vivo
and in vitro studies have implicated IL-3 in the survival,
proliferation, and differentiation of hematopoietic pro-
genitors/stem cells and also mature hematopoietic cells
(Ihle et al., 1983; Metcalf et al., 1986). IL-3 is produced
by activated T and NK cells, keratinocytes, some mye-
loid, stromal, neuronal, and microglia cells. IL-3 recep-
tors are expressed mainly by hematopoietic cells (e.g.,
HSCs, myeloid cells, B cells), although their expression
is also found in testis, placenta, and brain (Morikawa
et al., 1996). Most species express one receptor for IL-3,
formed by the IL-3Ra chain (Gorman et al., 1990) and
the common b chain (bc, shared with IL-5 and GM-CSF
*Correspondence: e.dzierzak@erasmusmc.nlreceptors). A second IL-3 receptor is expressed only in
the mouse and is formed by the bIL-3 chain in association
with the IL-3Ra chain (Gorman et al., 1992).
The effect of IL-3 on adult HSCs remains controversial.
IL-3 has been shown both to significantly increase
(Bryder and Jacobsen, 2000) and decrease (Peters
et al., 1996; van der Loo and Ploemacher, 1995; Yone-
mura et al., 1996) the expansion and/or self-renewal
capacity of adult HSCs. The seemingly contradictory
effects of IL-3 are most likely influenced by its concentra-
tion, the presence/absence of other cytokines, serum,
culture conditions, tested cell population, etc. Surpris-
ingly, the targeted disruption of the IL-3 (Lantz et al.,
1998) or IL-3 receptor genes (Nishinakamura et al.,
1995, 1996; Robb et al., 1995) in mice revealed only
very minor alterations of adult hematopoiesis. Hence,
the role of IL-3 was not further explored during embry-
onic HSC development.
HSC development in the mouse embryo is of intense
current interest. The first adult-type HSCs are autono-
mously produced at mouse embryonic day (E) 10.5
(>35 somite pairs, sp) in the intraembryonic AGM (aorta-
gonad-mesonephros) region (Medvinsky and Dzierzak,
1996; Muller et al., 1994). During midgestation, HSCs
are also found in the vitelline and umbilical arteries (V/U)
(de Bruijn et al., 2000), vascular labyrinth of the placenta
(Gekas et al., 2005; Ottersbach and Dzierzak, 2005), yolk
sac (YS), and fetal liver (FL). The Runx1 transcription fac-
tor is expressed in all these embryonic sites (North et al.,
1999) and is essential for the embryonic development of
HSCs (Okuda et al., 1996; Wang et al., 1996). Runx12/2
embryos die at E12/13 with a complete lack of AGM
and FL definitive hematopoiesis. Haploinsufficiency of
Runx1 results in reduced adult-repopulating ability and
alters the temporal and spatial distribution of HSCs
(Cai et al., 2000). Although several target genes of
Runx1 have been identified in hematopoietic cells (for re-
view, see Otto et al., 2003) and include the hematopoietic
cytokine genes IL-3 (Mao et al., 1999; Uchida et al., 1997)
and GM-CSF (Takahashi et al., 1995), these cytokines
have not been tested for their effects on embryonic
HSCs. Hence, we examined whether IL-3 and other cyto-
kines play a role in embryonic HSC development.
We show here, by using the Runx1 haploinsufficient
mouse model, that among the tested cytokines, only
IL-3 rescues Runx1+/2 AGM HSC numbers. IL-3, which
is expressed in the major embryonic vessels, acts as a
survival and proliferation factor for E11 AGM HSCs. It
also amplifies HSCs from E11 YS and placenta. Blocking
experiments and transplantation studies with IL-3 mu-
tant embryos reveal a role for IL-3 in the development
of HSCs and demonstrate that IL-3 acts on HSCs at the
earliest stages of their emergence in the mouse embryo.
Results
HSC Numbers Are Reduced in Runx1+/2AGMs
We have shown previously that Runx1+/2 embryos suf-
fer from defects in the temporal and spatial emergence
and/or maintenance of HSCs (Cai et al., 2000). To more
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172Figure 1. IL-3 Increases HSC Activity in E11
Runx1+/2 Tissue Explants
(A) Percentage of mice reconstituted with in-
jected donor cells (1, 0.3, 0.1, or 0.03 embryo
equivalent [ee]/mouse) from E11 Runx1+/+ or
Runx1+/2 AGM explants (n = 7). Donor chime-
rism was determined 4 months after trans-
plantation by semiquantitative PCR. Num-
bers above each bar represent ‘‘number of
reconstituted mice/total number trans-
planted.’’
(B) Percentage of mice reconstituted 4
months posttransplantation with donor cells
(0.3 ee) from Runx1+/2 AGM explants cul-
tured with cytokines (ng/ml): interleukin (IL)-
3 (n = 3), stem cell factor (SCF) (n = 7), granu-
locyte macrophage-colony stimulating factor
(GM-CSF) (n = 4), oncostatin M (OSM) alone
or in combination with SCF and/or basic
fibroblast growth factor (bFGF) (n = 3). The
hatched line indicates the percentage of
mice reconstititued with Runx1+/2 AGM ex-
plants cultured in the absence of added cyto-
kine (0.3 ee).
(C) Percentage of mice reconstituted 4
months posttransplantation with donor cells
(0.3 or 1 ee) from E11 Runx1+/+ and Runx1+/2
yolk sac (YS) (n = 7) and placenta explants
(n = 5) cultured in the absence or presence
of IL-3 (200 ng/ml).precisely evaluate the HSC defects observed inRunx1+/2
AGMs, we performed limiting dilution in vivo trans-
plantations of cells from cultured E11 Runx1+/+ and
Runx1+/2 AGM explants (described in Medvinsky and
Dzierzak, 1996). At greater than 4 months posttransplan-
tation, the percentage of reconstituted recipients is re-
duced in the groups receiving Runx1+/2 AGM explant
cells as compared to Runx1+/+ cells (Figure 1A). The fre-
quency of HSCs per Runx1+/+ and Runx1+/2 AGM was
determined by Poisson statistics (Figure S1A and S1B,
no cytokine), and the absolute number of HSCs was cal-
culated to be 1.7 HSCs per Runx1+/+ AGM and 0.5 HSC
per Runx1+/2 AGM (Table 1). Thus, Runx1+/2 E11 AGM
explants contain 3.4-fold fewer HSCs.
IL-3 Addition to Runx1+/2 AGM Explants
Rescues the HSC Deficiency
Since two known downstream targets of Runx1 are the
cytokine genes, IL-3 and GM-CSF, our hypothesis con-
cerning the Runx1+/2 AGM hematopoietic deficiency
was that these factors are important for the emergence,
survival, and/or expansion of HSCs and are not opti-
mally expressed in Runx1+/2 embryos. To test this,
Runx1+/2 AGM explants were cultured in the presence
of IL-3 or GM-CSF (20–200 ng/ml) and HSC activity
was assayed by in vivo transplantation. We also exam-
ined the effects of other cytokines that are known either
to act synergistically or to induce the in vitro endothelial/
hematopoietic differentiation of AGM cells (Mukouyamaet al., 1998). As shown in Figure 1B, the addition of GM-
CSF, SCF, OSM, and/or bFGF did not increase Runx1+/2
AGM HSC activity when compared to the control (no cy-
tokine, 26%). Some conditions induced a negative effect
Table 1. Frequencies and Numbers of HSCs per Runx1+/+ and
Runx1+/2 AGM Explants Cultured in the Absence or Presence of





a HSCs/AGMb AFc fHSCs HSCs/AGM AF
0 1/165709 1.7 — 1/497126 0.5 —
2 1/49713 5.9 3.5 1/49713 5.0 10
20 1/19885 14.7 8.6 1/16571 14.9 29.8
200 1/4971 58.6 34.5 1/14204 17.4 34.8
Runx1+/+ and Runx1+/2 AGM explants were cultured for 3 days prior
to transplantation in the absence (0) or in the presence of 2, 20, or
200 ng/ml of IL-3.
a Limiting dilution transplantations were performed (see Figure 1A
and Table S1), and Poisson statistics (Figure S1) was used to calcu-
late the frequencies (f) of HSCs.
b Number of HSCs per AGM was calculated by multiplying the fHSCs
with the average number of total cells per AGM. The number of cells/
AGM is 2.9 3 105 6 0.8 (n = 13) and 2.5 3 105 6 0.8 (n = 10) for
Runx1+/+ and Runx1+/2 embryos, respectively. When cultured in
the presence of IL-3, the number of cells/AGM is 2.9 3 105 6 1.0
(n = 10) and 2.5 3 105 6 0.7 (n = 10) for Runx1+/+ and Runx1+/2 em-
bryos, respectively.
c AF is the amplification factor of HSCs in the explant cultures per-
formed in the presence of IL-3 compared to no IL-3.
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173Figure 2. IL-3 Expressing Cells in E11 AGMs
IL-3 specific in situ hybridization on cryosec-
tions from E11 Runx1+/+ (A–D), Runx1+/2 (E
and F), and Runx12/2 (G and H) embryos.
Sections are at the level of the intersection
of the aorta with the vitelline artery. (B), (E),
and (G) show the dorsal aorta (Ao), and (C),
(D), (F), and (H) show the developing stomach
(St). (A) Dorsal aorta boxed-in bottom area
is shown in (B), and developing stomach
boxed-in top area is shown in (C). Arrows
highlight IL-3 expressing cells in the lumen
(arrow) and attached to the Ao endothelium
(arrow head) and also disseminated in the St
(arrows). As a positive control, cytospins of
WEHI3 cells were used (not shown). IL-3
sense mRNA probe showed no signal (not
shown). Magnification 203 (A) and 403
(B–H). (I) Flow cytometric plots of cells from
Runx1+/+ (top dot plot) and Runx1+/2 (bottom
dot plot) AGM explants intracytoplasmically
stained with anti-IL-3 antibodies. Percent-
age of positive cells is indicated. Represen-
tative plots are shown (n = 3). (J) Flow cyto-
metric plots of Runx1+/+ AGM explant cells
showing IL-3 expression in hematopoietic
(CD45+CD312), endothelial (CD452CD31+),
and nonhemato/nonendothelial (CD452CD312)
populations. Representative data are shown
(n = 2).(SCF and GM-CSF at 20 or 200 ng/ml, OSM at 20 ng/ml
alone or with SCF and/or bFGF). While OSM at high
concentration (200 ng/ml) had a slight positive effect
(33%), the only cytokine able to significantly increase
the HSC activity was IL-3. At a low concentration of IL-3
(20 ng/ml), repopulation by Runx1+/2 cells was found in
six out of six mice transplanted. Limiting dilution trans-
plantation of Runx1+/2 E11 AGM explants (0.03, 0.1,
0.3, and 1 ee) cultured with 2, 20, or 200 ng/ml of IL-3
revealed that HSC rescue was IL-3 dose dependent
(Table S1). These HSCs provide high-level multilineage
engraftment (T and B lymphoid and myeloid lineages)
in primary recipients and self-renew, as demonstrated
by secondary transplantation (Figure S2A). HSC num-
bers in Runx1+/2 explants cultured in 2 ng/ml IL-3 sur-
passed the number of HSCs in Runx1+/+ explants cul-
tured without IL-3 (Table 1 and Figures S1A and S1B).
In the presence of increasing concentrations of IL-3,
both Runx1+/+ and Runx1+/2 explants amplify HSC num-
bers, reaching a 35-fold increase as compared to start-
ing numbers. However, since the starting numbers of
Runx1+/2 HSCs are at least 3-fold lower than in Runx1+/+
AGMs, the total number of Runx1+/2 HSCs after IL-3
amplification remains 3-fold lower than in Runx1+/+
AGMs (Table 1). Thus, IL-3 acts in a dose-dependent
manner to amplify HSC activity in Runx1+/2 AGM
explants, rescuing this activity to levels achieved by
Runx1+/+ AGM explants in the absence of exogenous
IL-3.
Effects of Runx1 Deficiency and Exogenous IL-3
on Yolk Sac and Placenta HSCs
To evaluate if Runx1 haploinsufficiency affects HSCs in
the other major hematopoietic tissues, we performed
explant culture and transplantation experiments with
E11 Runx1+/2 YS and placenta. In contrast to the resultsof AGM transplantations, Runx1+/2 YS explants resulted
in a higher percentage of reconstituted recipients than
Runx1+/+ YS explants (Figure 1C) (Cai et al., 2000). The
absolute number of HSCs was at least 4-fold increased
in Runx1+/2 YS as compared to Runx1+/+ YS (Fig-
ure S1C). Also, HSCs were increased in Runx1+/2 as
compared to Runx1+/+ placenta explants (Figure 1C).
Thus, while Runx1+/2 embryos are deficient in AGM
HSCs, the YS and placenta contain more HSCs than nor-
mal. These Runx1 related changes suggest that a full
dose of Runx1 suppresses HSC activity in the YS and
placenta (but not in the AGM) and downstream targets
may differ between tissues.
To test if the growth effect of IL-3 was restricted to the
HSCs within the AGM, we performed transplantations
of cells from E11 Runx1+/2 YS and placenta explants
cultured in the presence of IL-3. The percentage of re-
constituted recipients was increased (to 100%) in the
groups receiving YS and placental cells cultured with
IL-3 (Figure 1C) as compared to those cultured without
IL-3. A similar increase was observed for Runx1+/+ YS
and placental explant cells cultured with IL-3 (data not
shown). Thus, similar to AGM HSCs, IL-3 also stimulates
the growth of YS and placental HSCs.
IL-3 Is Expressed in Wild-Type but Not
Runx1-Deficient Embryos
Since gene targeting studies showed no embryonic
lethality or gross hematological defects in adult IL-3-
deficient mice, the expression pattern of this cytokine
during midgestation had not been previously explored.
We performed IL-3-specific in situ hybridization on
transverse sections of E11 Runx1+/+, Runx1+/2, and
Runx12/2 embryos (Figure 2). Runx1+/+ sections contain
strongly IL-3-expressing cells within the lumen of the
aorta (Figure 2B, arrows), and some of these cells
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174Figure 3. IL-3 Receptor Chain Expression in
Embryonic Tissues and Sorted CD34+c-kit+
Cells from E11 Runx1+/+ and Runx1+/2 AGM
Explants
RT-PCR analysis of IL-3Rbc, bIL-3, and IL-3Ra
mRNA in (A) subdissected aorta/mesen-
chyme (AoM) and urogenital regions (UGR),
yolk sac (YS), and vitelline/umbilical vessels
(V/U) from E11 Runx1+/+ embryos and (B)
sorted CD34+c-kit+ cells from Runx1+/+ and
Runx1+/2 E11 AGM explants cultured in the
presence (+) or absence (2) of IL-3.2RT, neg-
ative control; b-actin, RNA loading control. (C)
Flow cytometric plots showing IL-3Ra and bc/
bIL-3 chain expression on CD34
+c-kit+ cells
from Runx1+/+ (top row) and Runx1+/2 (bot-
tom row) E11 AGM explants. Dot plots (left
panel) show the gate including CD34+c-kit+
cells. The percentage of IL-3R chain expres-
sion is shown for the CD34+c-kit+-gated
population.adhere closely to the endothelial wall (Figure 2B, arrow
head). IL-3-expressing cells localize also within the
developing stomach region (Figures 2C and 2D), skin,
cardinal veins, and vitelline artery (Figures S3A–S3C).
Sections through Runx1+/2 embryos show fewer IL-3-
expressing cells in these regions (Figures 2E and 2F
and Figures S3D and S3E), and no IL-3-expressing cells
are present in Runx12/2 embryo sections (Figures 2G
and 2H and Figures S3F and S3G). Thus, the presence
of IL-3-expressing cells in the normal midgestation
embryo and the diminished/absent expression of IL-3
in Runx1 mutant embryos demonstrate that IL-3 is
downstream of Runx1 in the mouse.
To determine the number and identify the lineage of
IL-3-expressing cells, we performed flow cytometry on
E11 Runx1+/+ and Runx1+/2 AGM cells. Intracellular
staining with an IL-3-specific antibody revealed 0.31%
and 0.13% of AGM cells positive for IL-3 (Figure 2I), rep-
resenting 688 and 298 IL-3+ cells per Runx1+/+ and
Runx1+/2AGM, respectively. Multicolor staining with an-
tibodies specific for hematopoietic (CD45), endothelial
(CD31), and lymphoid progenitors (IL-7R) revealed that
all IL-3-expressing cells are within the nonhemato/
nonendothelial CD452CD312 and IL-7R2 fractions of
Runx1+/+ and Runx1+/2 AGM cells (Figure 2J and data
not shown). Thus, although limited to a few cells of un-
known lineage, IL-3 is produced in the midgestation em-
bryo and may play a physiological role in HSC regulation.
CD34+c-kit+ AGM Cells Express IL-3 Receptors
IL-3 signaling is known to occur through IL-3Ra:bc and
IL-3Ra:bIL-3 surface receptors. We tested whether em-
bryonic hematopoietic tissues and enriched AGM
HSCs express the IL-3R subunits. Semiquantitative
RT-PCR shows bc and IL-3Ra but not bIL-3 expression
by all E11 Runx1+/+ tissues tested, aorta-mesenchyme
and urogenital ridge subregions of the AGM, YS, andthe V/U vessels (Figure 3A). CD34+c-kit+ cells sorted
from Runx1+/+ and Runx1+/2 AGM explants cultured in
the presence or absence of IL-3 also express bc and
IL-3Ra (Figure 3B). Expression levels do not appear to
differ between the two genotypes (except for a lower
IL-3Ra expression in the Runx1+/2 AGM cells). Interest-
ingly, in the presence of IL-3, bIL-3 begins to be ex-
pressed and the levels of IL-3Ra and bc expression
are increased in CD34+c-kit+ cells, indicating some au-
toregulation of these receptors.
Flow cytometric analyses with antibodies specific for
IL-3Ra and for both bIL-3 and bc chains confirm that
indeed the IL-3 receptors are expressed on the surface
of AGM cells (Figure 3C). In both Runx1+/+ and Runx1+/2
AGM explants, a small fraction of CD34+c-kit+ cells
showed expression of the IL-3Ra and bIL-3/bc chains.
IL-3R chains are not expressed by endothelial
(CD452CD31+) cells but are expressed by a very small
number of nonhemato/nonendothelial cells (CD452CD312)
(data not shown). Thus, phenotypically defined AGM
HSCs express all three IL-3 receptor chains, indicating
that IL-3 may mediate its effect directly on HSCs.
IL-3 Regulates AGM HSCs In Vivo
We next examined whether an absence of IL-3 interferes
with AGM HSC function. Two approaches were used:
blocking with an IL-3 specific antibody and a genetic
approach with IL-3 mutant mice. E11 Runx1+/2 AGM
explants were cultured prior to transplantation in the
presence of an IL-3-blocking antibody to neutralize
endogenous IL-3 or an IgG1 control antibody. As shown
in Table 2, the percentage of repopulated mice de-
creased from 30% to 5% in the presence of the IL-3-
blocking antibody. A similar decrease in the HSC activity
in E11 Runx1+/+ AGMs cultured in the presence of IL-3-
specific blocking antibody was also observed (data
not shown). Explants cultured in the presence of IgG1
IL-3 Regulates Embryonic HSCs
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These results show that the IL-3-blocking antibody spe-
cifically interferes with HSC activity and that IL-3 pres-
ent, and/or produced, in the AGM is important for the
survival and/or amplification of HSCs.
IL-3 mutant embryos were examined for AGM HSC
activity. We performed transplantations of E11 IL-3+/+,
IL-3+/2, and IL-32/2 AGM explant cells into adult irradi-
ated recipients. Transplantation of IL-3+/+ cells resulted
in 83.3% of recipients repopulated, while only 23.8% of
recipients were repopulated with IL-3+/2 cells (Table 2).
Of the 6 IL-32/2 embryos available for explant culture,
only 1 AGM resulted in hematopoietic repopulation
(16.7%). When the primary recipients were tested for
multilineage engraftment, high-level donor repopulation
was found in all hematopoietic tissues and in sorted my-
eloid, T lymphoid, and B lymphoid cells (Figure S2B, top
panel). Moreover, the transplantation of the BM from
these primary recipients into secondary adult irradiated
recipients resulted in similar high-level repopulation
(Figure S2B, bottom panel). Thus, HSCs from IL-3 defi-
cient embryos are functional (multipotential and self-
renewing) but are greatly reduced in E11 AGM explants.
To verify the in vivo requirement for IL-3 (in the ab-
sence of the explant culture step), we transplanted E11
Table 2. Effect of a Decrease or Total Absence of IL-3 on the HSC











None after explant 6/20 (30) 13–37
IgG1 after explant 9/30 (30) 12–49
Anti-IL-3 after explant 1/20 (5) 13
Gene targetedb
IL-3+/+ after explant 5/6 (83.3) 36–100
IL-3+/2 after explant 5/21 (23.8) 21–72
IL-32/2 after explant 1/6 (16.7) 26
Gene targetedc
IL-3+/+ direct 4/9 (44.4) 100
IL-3+/2 direct 4/12 (33.3) 17–100
IL-32/2 direct 0/5 (0) 0
a AGMs from E11Runx1+/2 embryos were cultured as explants in the
absence (none) or presence of 450 ng/ml of IgG1 (control) or block-
ing IL-3 antibody (Anti-IL-3) for 3 days prior to transplantation. One
embryo equivalent of cells were injected per mouse. Data from ex-
plant cultures in the absence or presence of IgG1 and anti-IL-3 are
from a total of five, six, and four independent experiments, respec-
tively.
b AGMs from E11 IL-3+/+, IL-3+/2, and IL-32/2 embryos were cultured
as explants for 3 days prior to transplantation. 0.3–1 ee of cells were
injected per mouse. Data from IL-3+/+, IL-3+/2, and IL-32/2 explant
cultures are from a total of two, three, and two independent experi-
ments, respectively.
c Cells from IL-3+/+, IL-3+/2, and IL-32/2 E11 AGMs (1 ee) were di-
rectly injected into irradiated adult recipients. Data from IL-3+/+
and IL-3+/2 transplantations are from a total of three and four inde-
pendent experiments. Data from IL-32/2 transplantations are from
one experiment. Only mice with R10% donor chimerism in the pe-
ripheral blood at >4 months after transplantation were included as
positive.
d Donor cell contribution to peripheral blood of individual recipient
mice was determined by semiquantitative PCR.IL-3 mutant AGMs directly into irradiated adult recipi-
ents. Again, HSCs were decreased in IL-3+/2 AGMs
and were undetectable in IL-32/2 AGMs (Table 2). Simi-
lar results were found when IL-3 mutant E11 YS and pla-
centa were transplanted directly (data not shown). Thus,
we conclude that wild-type levels of IL-3 are required for
the growth of normal numbers of HSCs as they emerge
in the mouse embryo.
Proliferation and Survival Effects
of IL-3 on Runx1+/2 HSCs
To determine if IL-3 promotes an increase in HSC num-
bers by proliferation or survival, we first analyzed the ab-
solute number of two phenotypically enriched HSC pop-
ulations (CD34+c-kit+ and Ly6A-GFP+c-kit+) (de Bruijn
et al., 2002; Sanchez et al., 1996) in E11 Runx1+/+ and
Runx1+/2 AGM explants after culture with and without
IL-3. In the absence of exogenously added IL-3, the
number of CD34+c-kit+ cells inRunx1+/2AGMs is slightly
lower than in Runx1+/+ AGMs (Figure 4A). In the pres-
ence of IL-3, CD34+c-kit+ cells increase in both
Runx1+/+ and Runx1+/2 AGMs. We also observed simi-
larly increased numbers of Ly6A-GFP+c-kit+ cells in
AGM explants cultured with IL-3 (data not shown).
Hence, IL-3 induces an increase in the absolute number
of phenotypically defined HSC populations in both
Runx1+/+ and Runx1+/2 AGMs. The cell-cycle status of
c-kit+ cells (a broader population of progenitors includ-
ing HSCs) from E11 Runx1+/2 AGMs cultured in the
absence or presence of IL-3 was also analyzed. BrdU
staining revealed that IL-3 induces a small percentage
of c-kit+ cells to exit G0/ G1 (Figure 4B). Moreover, Ki67
staining shows that in the presence of IL-3, some G0
cells enter into G1. Thus, IL-3 appears to act as an
HSC proliferation factor.
We further tested if IL-3 affects the proliferation and/
or survival of AGM HSCs in a two-step culture system
(Figure 4C). The first step is the AGM explant culture in
the presence/absence of IL-3. The second step is an
amplification culture (with equivalent numbers of har-
vested CD34+c-kit+ cells) that allows for a more direct
comparison of the influence of IL-3 on the HSC popula-
tion during step one. Following the step-one culture of
E11 Runx1+/+ and Runx1+/2 AGM explants, hematopoi-
etic (CD45+) cells were analyzed by flow cytometry for
apoptotic markers. As shown in Figure 4Ca, in the ab-
sence of IL-3, the percentage of healthy cells (Annexin-
V27AAD2) is lower, and the percentage of preapoptotic
cells (AnnexinV+7AAD2) is higher in Runx1+/2 explants
as compared to Runx1+/+ explants. When IL-3 was pres-
ent in the culture, the percentages of healthy and prea-
poptotic CD45+ cells in Runx1+/2 explants are restored
to percentages observed in the Runx1+/+ explants (no
IL-3). The same results were obtained from Runx1+/2
AGMs characterized by the expression of hematopoietic
stem/progenitor markers c-kit, Sca-1, or CD34 (data not
shown). Thus, hematopoietic cells in Runx1+/2 AGM ex-
plants are more sensitive to apoptosis than Runx1+/+
cells, and addition of IL-3 to the cultures promotes their
survival.
Following step one, Runx1+/+ and Runx1+/2 AGM ex-
plants were harvested and CD34+c-kit+ cells were
sorted, seeded at a density of 3.5 3 103 cells per well,
and cultured in suspension for 10 days in the presence
Developmental Cell
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IL-3 on AGM HSCs In Vitro
(A) Absolute number of CD34+c-kit+ cells per
Runx1+/+ and Runx1+/2 AGM explants cul-
tured in the absence/presence of IL-3 (200
ng/ml) was calculated from the average num-
ber of cells per AGM and the percentage of
CD34+c-kit+ cells (see legend of Table 1)
(n = 3–5). Fold increase of CD34+c-kit+ cells
in the presence of IL-3 is indicated.
(B) Cell cycle status of c-kit+ cells from
Runx1+/2 AGM explants cultured in the pres-
ence/absence of IL-3 (200 ng/ml). BrdU
(20 mM) incorporation was analyzed by flow
cytometry and the absolute number of c-kit+
cells in G0/G1 was calculated (n = 3). Ki67
and 7AAD stainings discriminate cells in G0
from cells in G1 phase (representative ex-
periment shown; n = 2). Data shown are the
mean 6 SD of three experiments.
(C) A two-step culture of Runx1+/+ and
Runx1+/2 AGMs was performed in the ab-
sence/presence of IL-3 (200 ng/ml). Step one, explant culture with/without IL-3. Step two, CD34+c-kit+ cells were sorted from AGM explants,
seeded at 3.5 3 103 cells/well, and cultured in suspension for 10 days with IL-3 (200 ng/ml). (Ca) Apoptotic status of CD45+ cells from AGM ex-
plants after step one culture. Flow cytometry determined the proportions of healthy (AnnexinV27AAD2) and preapoptotic (AnnexinV+7AAD2)
CD45+ cells (n = 3). (Cb) Percentage of CD34+c-kit+ cells remaining after two-step culture as determined by flow cytometry (n = 3). Dot plots
are shown for Runx1+/2 AGM cells. (Cc) Absolute numbers of CD34+c-kit+ cells obtained after the two-step culture (n = 4). Hatched line indicates
input number (3.5 3 103 cells/well).of IL-3. When no IL-3 was present during the step one
explant culture, we observed a complete disappearance
of Runx1+/2 CD34+ckit+ cells in the step two suspension
cultures (Figures 4Cb and 4Cc). This is consistent with
increased apoptotic activity observed by Annexin stain-
ing. In contrast, when IL-3 was included during step one,
Runx1+/2 CD34+ckit+ cells survived and were increased
2.6-fold in the suspension culture as compared to the
input cell number. Runx1+/+ CD34+ckit+ cells were also
increased (8.3-fold) in the step two culture when IL-3
was present during step one. Thus, IL-3 promotes the
survival and proliferation of phenotypically defined
HSCs in E11 AGM explants.
IL-3 Promotes the Early Detection
of AGM and YS HSCs
Since IL-3 has such potent effects on E11 HSC survival
and proliferation, we tested whether IL-3 could also af-
fect hematopoiesis at earlier stages. Thus far, adult-re-
populating HSCs have been detected only in embryos
from the 35 somite pair (sp) stage (E10.5) onward, sug-
gesting that this is a critical time point for their emer-
gence in the AGM region. To test for effects of IL-3 prior
to this time point, we performed explant cultures of early
E10 AGMs (30–34 somites pairs) in the absence or pres-
ence of IL-3 and measured HSC activity by in vivo long-
term repopulation of irradiated adult recipients. Trans-
plantation of cells (2–2.5 ee) from E10 AGM explants
cultured with IL-3 resulted in 64% of recipients repopu-
lated, while none of the recipients (0/17) were repopu-
lated with cells from AGMs cultured in the absence of
IL-3 (Table 3). Successful repopulation was also ob-
tained with the injection of as few as 1 ee of E10 AGM
cells (Table 3). Indeed, 20% of the mice transplanted
were reconstituted (with one recipient showing 64% do-
nor chimerism). E10 HSCs result in high-level multiline-
age engraftment (normal levels of T and B lymphoid
and myeloid lineage cells) in primary recipients (Fig-
ure S2C, top panel) and successful high-level repopula-tion in secondary recipients (Figure S2C, bottom panel).
In parallel, we also transplanted the cells from E10 YS
and placenta (Table 3). Similar to the AGM transplanta-
tion results, 20% of the mice injected with 1 ee of E10
YS were reconstituted (including one recipient with
45% donor chimerism). No mice were reconstituted af-
ter the injection of E10 placenta. Thus, IL-3 promotes
HSC detection in early E10 AGM and YS either through
the survival and/or proliferation of a limiting number of
previously undetectable HSCs or the emergence of
new HSCs.
Discussion
We have demonstrated here that the well-known adult
hematopoietic cytokine IL-3 plays an in vivo role in the
amplification of the HSC pool in the midgestation mouse
embryo. We have also shown that exogenously pro-
vided IL-3 promotes HSC activity in the early E10 AGM
and YS (30–34 somites pairs), at a time when typically
no HSCs are detected (as stringently defined by in vivo
long-term, high-level multilineage repopulation in irradi-
ated adult wild-type recipients). Considering that this
cytokine does not produce dramatic effects in the hema-
topoietic system of the adult, our finding that IL-3 is an
important embryonic HSC regulator offers new possibil-
ities for the examination and manipulation of the earliest
events in HSC fate determination and growth.
Hematopoietic Growth Factors in the Embryo
The emergence and growth of HSCs in the midgestation
mouse embryo is complex and the processes leading to
the establishment of these cells are influenced by the
specific microenvironments of the hematopoietic sites.
Careful dissection of the AGM, YS, and placental micro-
environments and study of the HSCs that reside within
them can reveal important regulatory molecules. Several
factors already shown to affect early hematopoietic
and endothelial cell development include the vascular
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177endothelial growth factor (VEGF) (Shalaby et al., 1995),
TGFb1 (Dickson et al., 1995), M-CSF (Minehata et al.,
2002), and the IL-6 family member, oncostatin M (Mu-
kouyama et al., 1998). Many other growth factors
(TPO, Flt3L, G-CSF, IL-1b, IL-6, Weche, IL-11, LIF)
have been found to be expressed in cell lines from the
AGM microenvironment (Ohneda et al., 1998, 2000; Oos-
tendorp et al., 2002) and await further study.
Until our studies, the expression of IL-3 in the embryo
was undetermined, and its function during development
was thought to be redundant due to the viability of IL-32/2
mice and the lack of major hematopoietic defects in the
adult. Sensitive in situ hybridization analysis revealed
the expression of IL-3 in appropriate sites and tissues
at E11, coincident with HSC activity. Similarly, expres-
sion of IL-3 receptors was found on E11 cell populations
enriched for HSC activity. We also confirmed the pres-
ence of IL-3- and IL-3R-expressing cells in the early
E10 AGM region and found upregulated IL-3R expres-
sion when AGMs were cultured in presence of IL-3
(data not shown). In the two-step in vitro culture, only
AGMs cultured with IL-3 in step one were able to yield
CD34+ckit+ cells that survived and proliferated in step
two. Furthermore, HSCs in E11 IL-3+/2 AGMs do not ap-
pear to amplify (as do IL-3+/+ AGM HSCs) during explant
culture. Thus, IL-3 is an important early regulator of
HSCs, which most likely becomes redundant as the
expression of other growth factors is initiated at later
developmental stages.
The Relationship of Runx1 and IL-3
Initially we used Runx1 haploinsufficient mice as a model
to test if adult cytokines play a role in embryonic hema-










AGM 2–2.5 2 0/17 (0) 0
+ 9/14 (64.3) 1; 27; 83; 88;
95; 98; 99;
100; 100
1 2 0/8 (0) 0
+ 3/15 (20) 4.8a; 8.9a; 64b
YS 1 2 0/9 (0) 0
+ 3/15 (20) 3.6b; 9.1a; 45a
Placenta 1 2 0/15 (0) 0
+ 0/10 (0) 0
Early E10 (30 to 34 somite pairs [sp]) AGM, YS, and placenta explants
were cultured in the absence (2) or the presence (+) of 200 ng/ml of
IL-3 for 3 days prior to transplantation. Only mice withR1% donor
chimerism in the peripheral blood at 2 and 4 months after transplan-
tation were included in the number of repopulated mice. Donor cell
chimerism in the peripheral blood of individual recipient mice was
determined by semiquantitative PCR. Data are from a total of three
to six independent experiments. ee corresponds to the number of
embryo equivalent injected per mouse. AGMs from embryos ranging
from 30 to 34 sp were pooled for the transplantations of 2–2.5 ee.
a Mice reconstituted with cells from 33 sp embryos.
b Mice reconstituted with cells from 34 sp embryos.topoiesis since cytokine genes IL-3 (Mao et al., 1999;
Uchida et al., 1997) and GM-CSF (Takahashi et al.,
1995) are known Runx1 targets. Out of the panel of cyto-
kines tested, only IL-3 was able to rescue the Runx1+/2
AGM HSC defect. If IL-3 is indeed one of the Runx1
downstream effectors, at least some aspects of the
HSC defects in IL-3+/2 AGMs should be similar to
Runx1+/2 AGMs. We found an approximately 2-fold de-
crease in repopulation potential in both Runx1+/2 AGM
cells and IL-3+/2 AGM cells, as compared to wild-type
AGMs. Moreover, we found that IL-3 expression, nor-
mally present in circulating cells and developing stom-
ach cells of wild-type E11 embryos, was absent and
much decreased in Runx12/2 and Runx1+/2 embryos,
respectively. Thus, as one of many putative targets of
Runx1, IL-3 is responsible for some part of the AGM de-
fects (survival and/or proliferation of HSCs) observed in
the Runx1 mutant embryos.
A direct role for Runx1 in activating the transcription of
IL-3 would require Runx1 expression in the AGM micro-
environment. Runx1 expression has been found in some
circulating cells within the lumen of the E11.5 aorta
(North et al., 2002). Since some IL-3 expressing cells cir-
culate, and it has been reported that circulating cells can
attach to the aortic endothelium (Takakura et al., 1998), it
is possible that localized release of IL-3 at these sites
where hematopoietic clusters emerge from the endothe-
lium affects the survival/expansion of newly formed
HSCs. Flow cytometry and RT-PCR analysis suggest
that the IL-3-producing cells are not hematopoietic or
endothelial (CD452CD312 cells) nor early T cell progen-
itors (IL-7R2) or hematopoietic ‘‘lymphoid tissue inducer
cells’’ (CD4+CD32IL-7Ra+) (D. Finke, personal communi-
cation). However, due to ontogenic expression changes
in hematopoietic markers and the finding that some
AGM hematopoietic cells are CD452 (Bertrand et al.,
2005; Matsubara et al., 2005), we cannot rule out the
possibility of their hematopoietic nature. Positive identi-
fication of these cells is ongoing.
The effects of Runx1 haploinsufficiency are more
wide spread than those of IL-3 haploinsufficiency. As
previously mentioned by Cai et al. (2000), HSC activity
in Runx1+/2 AGMs is decreased, while it is increased
in Runx1+/2 YS. We confirmed this and found that
Runx1+/2 YS contains at least 4-fold more HSCs
than Runx1+/+ YS. We have additionally shown that
the placentas of Runx1+/2 embryos are increased in
HSCs. The discordant effect of half a dose of Runx1
in the AGM and the extraembryonic tissues is puzzling.
Runx1+/2 BM has been reported to contain a decreased
number of HSCs but has increased numbers of progeni-
tor cells (Sun and Downing, 2004). Also, an acceleration
of the mesodermal commitment and specification to
Blast-CFC and hematopoietic lineages was reported in
the Runx1+/2 embryoid bodies (Lacaud et al., 2004). As
we have preliminary data showing an early appearance
(E10) of HSCs inRunx1+/2 YS and placenta, it is possible
that the higher HSC numbers found at E11 in these tis-
sues are a consequence of HSC accumulation (and is un-
related to IL-3). This would suggest that normal levels of
Runx1 suppress the appearance of HSCs in the YS and
placenta while promoting HSC appearance in the AGM.
This could occur at the level of Runx1-interacting pro-
teins in the specific microenvironments. Such interacting
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178partners could positively/negatively regulate transcrip-
tion in a spectrum of downstream targets. Nonetheless,
we have shown that IL-3 acts similarly in E11 AGM, YS,
and placenta to increase HSC numbers, supporting the
notion that IL-3 is a Runx1 target.
How Does IL-3 Regulate AGM HSCs?
Our data showing expression of IL-3R on CD34+c-kit+
AGM enriched HSC populations are consistent with
the expression of IL-3Rs on adult mouse BM HSCs
(RholoLin2Ly6A/E+c-kit+) (McKinstry et al., 1997). Inter-
estingly, the levels of IL-3R expression on adult HSCs
appear to be directly related to the proliferative re-
sponse (Murthy et al., 1989), and thus, it is thought
that the low level expression of IL-3R on adult BM
HSCs protects them from inappropriate proliferation.
The low expression of IL-3R on AGM HSCs and the
lack of receptor expression on most other AGM cells
suggest that IL-3 acts directly on AGM HSCs.
IL-3 is known to act as a survival factor. In vitro analy-
ses of AGM hematopoietic populations (including
CD34+c-kit+) demonstrate that IL-3 promotes their sur-
vival. This is in agreement with the survival effect of IL-3
on adult hematopoietic cells (Kinoshita et al., 1995;
Lotem and Sachs, 2002) and the fact that survival path-
ways function in AGM HSCs (Orelio et al., 2004). IL-3
also acts as a proliferation factor. We have shown by
in vivo transplantation assays that IL-3 acts to increase
the absolute number of AGM HSCs. Our in vitro cul-
ture and phenotypic studies demonstrate that IL-3 in-
creases the number of AGM HSC-enriched populations
(CD34+c-kit+ and Ly6A-GFP+c-kit+) by promoting prolif-
eration. Thus, IL-3 acts to increase E11 AGM (and most
likely YS and placenta) HSC numbers by both processes.
In contrast to the apparent hematopoietic normality of
adult IL-32/2 and IL-3R2/2 (bc, bIL-3, and IL-3:bc) mice
(Lantz et al., 1998; Nicola et al., 1996; Nishinakamura
et al., 1995, 1996; Robb et al., 1995), we found a decrease
in AGM HSCs in IL-3+/2 and IL-32/2 embryos by both
direct transplantation and transplantation after explant
culture. HSCs are also decreased in IL-3 mutant E11
YS and E11/E12 placenta (by direct transplantation,
not shown). This suggests that while IL-3 shares func-
tional redundancy with other cytokines for HSC growth
in the adult, this is not the case in the embryo. In early/
midgestation embryos the functionally overlapping cy-
tokines or their receptors may not yet be expressed,
thus revealing an early role for IL-3 in the expansion of
the first HSCs. We propose that the limited numbers of
HSCs surviving in IL-3+/2 and IL-32/2 AGMs may be suf-
ficiently expanded at later developmental times by re-
dundant cytokines to provide a normal adult hematopoi-
etic system. Although less likely (since HSCs are not
completely absent in IL-32/2 mice), IL-3 may influence
the de novo generation of HSCs in the AGM, as well as
in the placenta and YS (Cai et al., 2000; Gekas et al.,
2005; Kumaravelu et al., 2002; Ottersbach and Dzierzak,
2005). We found that the addition of IL-3 to explant cul-
ture of early E10 AGM and YS (30–34 sp) promotes a high
level of HSC activity, prior to the time when they are nor-
mally detected. As others have detected multipotential
in vivo repopulating cells in the AGM and YS at pre-
E10 stages when transplanted under less stringent con-
ditions (neonatal [Yoder et al., 1997] or immunodeficientadult mice [Cumano et al., 2001]), IL-3 may promote the
induction of HSCs from these earlier hematopoietic pro-
genitors or alternatively, from other precursors. To test
the HSC induction properties of IL-3, we attempted to
rescue the complete HSC deficiency of Runx12/2 em-
bryos. We explant cultured E11 Runx12/2 AGM or V/U
arteries in presence of IL-3 (200 ng/ml) for 3 days and
transplanted these cells into irradiated adult recipient
mice. No repopulation was obtained even at 9 months
posttransplantation of 1 ee of Runx12/2 AGM (0/5 recip-
ients repopulated, n = 3) or 3 ee of Runx12/2 AGM (0/3,
n = 1) or V/U cells (0/3, n = 1). These data suggest that
IL-3 does not promote the de novo generation of HSCs
but most likely acts as a survival and proliferation factor
for preexisting HSCs that were undetectable due to
limiting numbers. Thus, despite its long history of study,
IL-3 is one of the earliest acting HSC cytokines and is an
important factor in the future studies of HSC fate deter-
mination and expansion in the embryo.
Experimental Procedures
Mice and Embryo Generation
Embryos were generated as indicated in Table S2. The date of vag-
inal plug discovery was considered E0. Animals were housed
according to institutional guidelines with free access to water and
food. Animal procedures were carried out in compliance with the
Standards for Humane Care and Use of Laboratory Animals.
Dissections, Explant Cultures, and Cell Preparation
Tissues were dissected from E10, E11, and E12 embryos (Robin
and Dzierzak, 2005) and dissociated by collagenase treatment
(0.12% w/v, type I, Sigma) for 1 hr. In some cases, whole tissues
explants were cultured for 3 days at 37C on permeable membrane
filters in myeloid long-term medium (StemCell Technologies) with
hydrocortisone (1026 M, Sigma). Placenta explants were cut into
small pieces before culture on the filter. Medium was supplemented
with 0, 1, 2, 20, or 200 ng/ml of cytokines (recombinant murine IL-3
[BD Pharmingen], SCF [AbCys], GM-CSF [R&D Systems], Oncosta-
tin M [R&D Systems], bFGF [R&D Systems]) or with 450 ng/ml of
IL-3-blocking antibody or IgG1 as a control (BD Pharmingen).
In Vivo Transplantation Assay
Intravenous injection of genetically marked cells into irradiated adult
female recipients was as previously described (Robin and Dzierzak,
2005). 129/SV 3 C57BL/6, C57BL/6, (CBA 3 C57BL/10), or BALB/c
mice were exposed to a split dose of 9 Gy of g-irradiation (137Cs
source) and injected with several dilutions of cells (0.03, 0.1, 0.3,
or 1 embryo equivalent [ee]). 2 3 105 spleen cells (recipient back-
ground) were coinjected to promote short-term survival. Mice
were maintained on 0.16% Neomycin (Sigma) water. Blood DNA
was obtained at 4 months after transplantation and analyzed for do-
nor cell genetic markers by semiquantitative PCR (Runx1, Neo, hb-
globin, and/or Ymt) (Cai et al., 2000; Muller et al., 1994; Strouboulis
et al., 1992). The percentage of donor chimerism was determined
from phosphoimaging of ethidium bromide stained gels (Image-
quant) and calculated from a standard curve of DNA control dilutions
(0%, 1%, 3%, 6%, 10%, 30%, 60%, and 100% donor marker). Recip-
ients of E11 and E10 cells were considered repopulated only when
donor chimerism was respectively >10% and >1%. HSC frequencies
were determined with Poisson statistics based on the logarithmic
proportion of nonrepopulated mice and the doses of injected cells.
HSC number/tissue was estimated according to the average total
cell number/explant tissue (see legend Table 1).
Flow Cytometric Analysis after Surface/Intracytoplasmic
Antibody Staining
Monoclonal antibodies (BD Pharmingen) include: APC or PE-anti-
c-kit (clone 2B8), FITC-anti-CD34 (RAM 34), FITC-anti-CD31, APC
or PE-anti-CD45, PE-anti-IL3Ra chain (kindly provided by Dr. Rode-
wald), PE-anti-bIL-3/bc, and APC-anti-CD127 (IL-7 Receptor a chain).
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179Cells were incubated with antibodies for 20 min on ice, washed
twice, and resuspended in PBS supplemented with 10% FCS and
7AAD (Molecular Probes, Leiden, The Netherlands) or Hoechst
33258 (1 mg/ml, Molecular Probes) for dead cell exclusion. Cells
were analyzed on a FACScan or FACS Aria (Becton Dickinson). For
intracytoplasmic PE-anti-IL3 antibody staining, cells were fixed
and permeabilized with Cytofix/Cytoperm (BD Pharmingen). For ap-
optotic status, cells were stained with FITC-anti-AnnexinV (BD Phar-
mingen) and 7AAD. For cell-cycle analysis, BrdU (20 mM, Sigma) was
added to explant cultures during the final 16 hr. After collagenase
treatment, cells were stained with PE-anti-c-kit and FITC-BrdU
(BrdU Flow kit; BD Pharmingen). FITC-anti-Ki67 (BD Pharmingen)
and 7AAD stainings were also performed.
RT-PCR Analysis
Total RNA was extracted from 10–203 103 sorted cells or embryonic
tissues with Trizol (Invitrogen). RNA was treated with RNase-free
DNaseI (Promega). After phenol/chloroform/isoamyl alcohol extrac-
tion and ethanol precipitation, cDNA synthesis was performed by
using oligodT primers (Promega) and reverse transcriptase (Super-
script II, Stratagene). Table S3 lists the primer sequences and PCR
fragment sizes.
In Situ Hybridization
A 606 bp product was obtained by RT-PCR with cDNA prepared
from WEHI-3 cells and the IL-3-specific primers (50-TTGGAGGACC
AGAACGAGAC-30 and 50-CATTTGATGGCATAAAGGAATG-30) and
cloned into the p-GEM-T Easy (Promega). Ten micron cryosections
were prepared from quick frozen embryos and hybridized with
digoxigenin-labeled riboprobes as described previously (Otters-
bach and Dzierzak, 2005).
Supplemental Data
Supplemental Data include graphs of Poisson statistics used to cal-
culate the HSC frequencies (Figure S1), hematopoietic multilineage
engraftment data (Figure S2), IL-3 mRNA expression analysis in
Runx1 mutant skin and embryonic vessels (Figure S3), transplanta-
tion data on the dosage effect of IL-3 (Table S1), details of embryos
used in the studies (Table S2), and RT-PCR primer sequences (Table
S3) and are available at http://www.developmentalcell.com/cgi/
content/full/11/2/171/DC1/.
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